» Articles » PMID: 23671416

Challenges in Detecting HIV Persistence During Potentially Curative Interventions: a Study of the Berlin Patient

Abstract

There is intense interest in developing curative interventions for HIV. How such a cure will be quantified and defined is not known. We applied a series of measurements of HIV persistence to the study of an HIV-infected adult who has exhibited evidence of cure after allogeneic hematopoietic stem cell transplant from a homozygous CCR5Δ32 donor. Samples from blood, spinal fluid, lymph node, and gut were analyzed in multiple laboratories using different approaches. No HIV DNA or RNA was detected in peripheral blood mononuclear cells (PBMC), spinal fluid, lymph node, or terminal ileum, and no replication-competent virus could be cultured from PBMCs. However, HIV RNA was detected in plasma (2 laboratories) and HIV DNA was detected in the rectum (1 laboratory) at levels considerably lower than those expected in ART-suppressed patients. It was not possible to obtain sequence data from plasma or gut, while an X4 sequence from PBMC did not match the pre-transplant sequence. HIV antibody levels were readily detectable but declined over time; T cell responses were largely absent. The occasional, low-level PCR signals raise the possibility that some HIV nucleic acid might persist, although they could also be false positives. Since HIV levels in well-treated individuals are near the limits of detection of current assays, more sensitive assays need to be developed and validated. The absence of recrudescent HIV replication and waning HIV-specific immune responses five years after withdrawal of treatment provide proof of a clinical cure.

Citing Articles

HIV controllers: hope for a functional cure.

Deng Z, Yan H, Lambotte O, Moog C, Su B Front Immunol. 2025; 16:1540932.

PMID: 40070826 PMC: 11893560. DOI: 10.3389/fimmu.2025.1540932.


Immune-mediated strategies to solving the HIV reservoir problem.

Kulpa D, Paiardini M, Silvestri G Nat Rev Immunol. 2025; .

PMID: 39948261 DOI: 10.1038/s41577-025-01136-7.


Changes in cerebrospinal fluid proteins across the spectrum of untreated and treated chronic HIV-1 infection.

Hu Z, Cinque P, Dravid A, Hagberg L, Yilmaz A, Zetterberg H PLoS Pathog. 2024; 20(9):e1012470.

PMID: 39316609 PMC: 11469498. DOI: 10.1371/journal.ppat.1012470.


Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies.

Chatterjee A, Matsangos A, Latinovic O, Heredia A, Silvestri G Arch Stem Cell Ther. 2024; 5(1):5-13.

PMID: 39301092 PMC: 11412077. DOI: 10.46439/stemcell.5.020.


Exceptional, naturally occurring HIV-1 control: Insight into a functional cure.

Salgado M, Migueles S, Yu X, Martinez-Picado J Med. 2024; 5(9):1071-1082.

PMID: 39013460 PMC: 11411266. DOI: 10.1016/j.medj.2024.06.008.


References
1.
Keele B, Derdeyn C . Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS. 2010; 4(5):352-7. DOI: 10.1097/COH.0b013e32832d9fef. View

2.
Alexaki A, Liu Y, Wigdahl B . Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008; 6(5):388-400. PMC: 2683678. DOI: 10.2174/157016208785861195. View

3.
Strain M, Lada S, Luong T, Rought S, Gianella S, Terry V . Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One. 2013; 8(4):e55943. PMC: 3616050. DOI: 10.1371/journal.pone.0055943. View

4.
Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, von Wyl V . Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology. 2008; 5:107. PMC: 2630982. DOI: 10.1186/1742-4690-5-107. View

5.
Finzi D, Blankson J, Siliciano J, Margolick J, Chadwick K, Pierson T . Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999; 5(5):512-7. DOI: 10.1038/8394. View